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Abstract: Cardiovascular diseases constitute a serious public health problem. It is
estimated that they are responsible for nearly 30% of world mortality. Regardless of the
developments in the diagnosis and management of cardiovascular diseases, their
incidence rate remains increasing. Therefore, newlines of drugs are needed to manage
the expanding population of patients with cardiovascular diseases. Even though the
most common existing treatments for cardiovascular diseases are synthetic molecules,
natural compounds, of different chemical classes, are also being tested. Medicinal
plants have been employed in the treatment of some cardiovascular diseases such as
congestive heart failure and hypertension many centuries ago. Recently, the traditional
remedies application for the treatment of different disorders is gaining revived
popularity. In this chapter, we will investigate the efficacy and safety of natural
products under preclinical studies and clinical trials with particular emphasis on their
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traditional uses and implementations in the primary health care system. The great
potential of medicinal plants and herbs will be discussed in light of the rising
prevalence of cardiovascular diseases as one of the most devastating global health
problems.

Keywords: Angina, Cardiovascular diseases, Clinical trials, Hypertension, Heart
failure, Ischemic heart diseases, Natural products.
1. INTRODUCTION
According to the World Health Organization (WHO) definition, cardiovascular
diseases (CVD) are the diseases associated with the heart and/or the blood vessels
[1]. Most common Cardiovascular disease (CVD) types include Hypertension,
Angina Pectoris, Atherosclerosis, Ischemic Heart Disease and Cerebral and
Venous Insufficiency.
There are many cardiovascular risk factors for the development and evolution of
CVD. According to “European guidelines on cardiovascular disease prevention in
clinical practice” which were published by the European Society of Cardiology,
there are two main categories of cardiovascular risk factor: modifiable and nonmodifiable factors [2, 3]. As for modifiable cardiovascular risk factors; they
include smoking, limited physical activity, inappropriate diet, overweight and
obesity or disturbed lipid profile. Non-modifiable individual risk factors include
genetic factors, sex, age or family history. Tobacco use is a major risk factor for
CVD as well as chronic respiratory diseases and cancer. Several reports showed
that proper nutrition, active physical lifestyle and avoiding tobacco are able to
decrease CVD risk [4, 5].
The incidence rate of cardiovascular diseases worldwide has increased drastically
during the last years. Cardiovascular diseases are considered one of the four main
non-communicable diseases (NCDs) accounting for serious threats next to
diabetes, cancer and chronic respiratory disease [6]. The WHO estimated that
more than 40 million deaths occurred in 2016 due to NCDs, of which 17.9 million
deaths were caused by cardiovascular diseases, accounting for 44% of all NCD
deaths [6]. Therefore, CVD are ranked as the leading cause of death worldwide.
CVD are presently one of the major causes of death worldwide. The current
strategic approaches for the treatment of CVD diseases involve many effective
drugs. However, the majority of these drugs have low safety profile and lead to
serious side effects. Natural products have constantly been considered a treasured
source for innovation of novel drug leads. Growing evidence suggests that
numerous natural compounds are invaluable sources of CVD remedies. In this
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review, the prevalence and the pathophysiology of CVD disorders are discussed.
Additionally, the great impact of medicinal plants and natural compounds for the
prevention and treatment of CVD disorders is addressed. Special emphasis is laid
on plant-derived products which are in pre-clinical or clinical trials.
2. ISCHEMIC HEART DISEASE AND CONGESTIVE HEART FAILURE
2.1. Pathophysiology of Ischemic Heart Disease
The narrowing of the coronary arteries which provide the cardiac muscle with
oxygenated blood is referred to as Ischemic Heart Disease (IHD), Coronary
Artery Disease (CAD), or Coronary Heart Disease (CHD). This narrowing leads
to ischemic damage of the myocardium. Although CAD can be asymptomatic in
some cases, myocardial ischemia usually causes chest pain and/or discomfort
known as angina pectoris (Hereafter discussed) due to an imbalance between local
oxygen supply to the myocardial tissue and its oxygen demand.
The primary cause of coronary artery narrowing is the process known as
atherosclerosis (Hereafter discussed in more detail in section 5). This process
involves the pathological deposition of oxidized cholesterol in the arterial wall. In
the early course of the disease, coronary endothelial cells become dysfunctional
with a reduction in the production of important mediators like nitric oxide and
prostacyclin. This can lead to vasospasms and impaired relaxation of the
coronaries. As the disease progresses, leukocytes infiltrate the coronary artery
wall causing inflammation, plaque formation and eventually thickening and
hardening of the vessel wall; as well as narrowing of the lumen which restricts
blood flow [7].
Severe and/or prolonged, myocardial ischemia eventually causes regional necrosis
of cardiac tissue (myocardial infarction). Depending on the location and size of
the necrotic area, disturbance of ventricular contraction happens. Myocardial
necrosis with more than 20% trans-mural involvement can cause permanent
cardiac wall motion abnormality [8]. Percutaneous Coronary Intervention (PCI) or
coronary artery bypass surgery (CABG) may be applied in severe cases [9]. If
blood flow is restored in a timely fashion, wall motion abnormalities might
recover within a few days [10]. In addition, ventricular remodeling also occurs
and can take several forms such as ventricular dilation or even aneurysm. The
greater the degree of left ventricular dysfunction, the greater the likelihood of
developing heart failure, arrhythmias, and even death may occur [11]. Ischemic
Heart Disease (IHD) remains among the major causes of mortality worldwide
[12].
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Risk factors include hypertension, diabetes mellitus, obesity, lack of exercise,
high serum cholesterol levels, family history of a heart attack before the age of 60
years, smoking, depression and alcohol consumption [13, 14]. A healthy lifestyle
is the best way to reduce the risk of developing CAD, including healthy dieting,
steady exercise, keeping a healthy body mass index and avoiding smoking.
2.2. Pathophysiology of Congestive Heart Failure (CHF)
Heart failure (HF) is a pathophysiological case that occurs when the heart cannot
pump enough blood to satisfy the requirements of the metabolizing tissues. With a
few exceptions, HF is usually due to defective myocardial contraction. Heart
failure, however, should be distinguished from circulatory failure, which is due to
decreased blood volume, damage to blood vessels, or decreased concentration of
oxygenated hemoglobin [7]. Although heart failure, by definition, results in
circulatory failure, the opposite is not necessarily true.
The underlying pathogenesis of the defective myocardium involves ischemic
damage, hemodynamic overload, ischemic damage, excessive neuro-humoral
stimulation, silent inflammatory responses, bacterial or viral infections, calcium
cycling abnormalities, extracellular matrix proliferation as well as ventricular
remodeling [15 - 17].
However, uncontrolled diabetes and long-standing hypertension are considered
the strongest risk factors of CHF in patients with coronary heart disease [18]. Age
is also a major risk factor for developing heart failure due to increased incidence
of atherosclerosis, myocardial wall stiffness, and hypertension, which promotes
an increased end-diastolic pressure in a rigid ventricle causing pulmonary edema
[19, 20]. With increased life expectancy, the incidence of CHF is projected to
more than double over the next two decades and its prevalence will rise ten times
between the age of 60 and 80 [21, 22].
Decreased myocardial contractility results in reduced ejection fraction (the
percent blood pumped out of the ventricle with respect to the end diastolic
volume). At the early stages of heart failure, the cardiac output might show
normal levels while resting but fails to increase proportionally with exertion.
Consequently, one of the most common symptoms and early signs of heart failure
is exercise-intolerance and rapid fatigue. As a result of decreased ejection fraction
and increased ventricle filling pressure (increased preload), blood accumulates in
the systemic venous bed and pulmonary circulation causing pulmonary and/or
peripheral edema depending on the type of heart failure being left-sided, rightsided or both [7]. Hence, a major goal of heart failure treatment is to increase
myocardial contractility and ejection fraction.
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The cardiac output reduction has a number of short-term circulatory and
hemodynamic consequences which are triggered by two main compensatory
mechanisms. First, a fast-nervous mechanism: Reduced volume of blood
delivered into the major arteries results in changes in baroreceptor signaling
which will trigger an increase in sympathetic activity [7, 23]. The increase in
sympathetic activity results in tachycardia (elevated heart rate) and increased
vascular tone. The increase of arterial tone is better causes increased peripheral
resistance (afterload), while higher venous tone causes an increase in venous
return (preload). Second, a slower renal mechanism: Decreased arterial blood flow
causes a reduction in renal perfusion and Renin-Angiotensin-Aldosterone System
(RAAS) activation [24]. The increased RAAS activity eventually causes increased
vascular tone (increased preload and afterload), retention of sodium and water in
the intravascular and interstitial compartments (increased preload), and long-term
changes in the myocardium. The excessive retention of fluid is responsible for
many of the clinical manifestations of heart failure including pulmonary
congestion, dyspnea, and peripheral edema, hence the name congestive heart
failure. Thus, alleviation of fluid retention and edema is another major goal of
treatment [7].
While the increase in sympathetic tone and activation of RAAS help maintain the
blood pressure and augment preload to maintain the perfusion to vital organs e.g.
heart and brain, they also result in maladaptive responses like pulmonary and
peripheral congestion, afterload mismatch, decreased energy efficiency, and
cardiac dilatation and remodeling. The gradual exacerbation of heart failure
symptoms is clinically described as chronic decompensated heart failure [20, 25].
The patients are usually assigned to one of four different stages of CHF based on
the severity of the symptoms, with earlier stages having no or mild symptoms and
the end-stage involving failure to do daily activities.
Congestive heart failure generally has a poor prognosis with about a year
mortality of 33 - 35% [26, 27]. Regardless of the developments in medicine, the
treatment of heart failure still represents a challenge to healthcare providers due to
the high rate of hospital readmissions besides mortality and morbidity increase.
The key targets of heart failure treatment are to alleviate symptoms, improve
prognosis and decrease mortality, and prevent organ system damage [28, 29].
2.3. Natural Products for Management of Congestive Heart Failure and
Ischemic Heart Disease
Nutraceuticals are getting more popular all over the world as an adjunct to
conventional therapy for cardiovascular diseases [30]. Through multiple
mechanisms, natural products can provide several benefits to treatment regimens.
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First, products with antioxidant activity might delay the onset and slow the
progression of CAD by preventing the oxidation of the LDL cholesterol [31]. In
addition, antioxidant compounds prevent oxidative damage that occurs due to
ischemia / reperfusion in patients with advanced CAD [32]. They also improve
vascular and endothelial function through increased levels of nitric oxide [33].
Second, their anti-inflammatory effects help thwart atherosclerosis, vascular
plaque formation, myocardial remodeling, and reperfusion damage. Third, some
natural products have potent anti-atherogenic effects due to their ability to
improve the blood lipid profile. In addition to antioxidant and anti-inflammatory
actions, nature may play other beneficial roles such as anti-apoptotic effects,
anticoagulant activity, vasodilation, diuretic, and others. Here, we briefly discuss
some of the recent advances in using natural products to manage and protect
against CAD and CHF.
2.3.1. Flavonoids
A large class of secondary plant metabolites (flavones, flavonols, flavanones,
isoflavones and anthocyanidins) found in onions, citrus fruits, berries, tea and
cocoa [34, 35]. They are known for their antioxidant activity which can avert the
oxidative stress caused by Reactive Oxygen Species (ROS) [36, 37]. This effect
protects against low density lipoprotein (LDL) cholesterol oxidation (an early step
of atherosclerosis), decreases platelet aggregation, lessens the ischemic damage,
and improves blood vessel function [38, 39]. Flavonoids have been also shown to
also have anti-inflammatory activity [40, 41].
The role of flavonoids to protect against cardiovascular diseases is, however,
controversial [30]. Several studies have shown a reduction in the incidence and
mortality of CAD in cases those consuming flavonoid rich diets [42, 43]. Other
studies showed no relationship between flavonoid consumption and the incidence
of CAD [44 - 46]. Nonetheless, in one of these studies, flavonoids reduced
subsequent coronary events in patients diagnosed with CHD [44]. A meta-analysis
that included several studies (including ones that showed no benefits), suggested
that consumption of flavonoid rich tea reduces the risk of cardiovascular diseases
by more than 10% [47].
2.3.2. Resveratrol
Resveratrol is produced by plants due to injury or fungal infection; it is a naturally
occurring phytoalexin [48]. High amount of resveratrol is present in the seeds and
skin of grapes and in peanuts [49, 50]. It is currently available in the market as a
nutritional supplement. There is strong experimental and clinical evidence that
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resveratrol exerts cardio protective effects [51].
The cardio protective effects of resveratrol are due to its antioxidant,
antithrombotic, antiplatelet, anti-apoptotic and anti-atherosclerotic activities, in
addition to improved vascular and endothelial function [52 - 54].
2.3.3. Lycopene
Lycopene is a natural red pigment synthesized by some photosynthetic organisms
e.g. plants and algae aiming at absorbing light for photosynthesis and also to
protect against sunlight. Lycopene and other carotenoids give the bright orange
and red colors to many fruits and vegetables. The major source of lycopene in the
diet is tomato-based products.
Dietary intake of tomato and its products has shown a negative correlation with
CAD and myocardial infarction [55, 56]. The ideal daily intake of lycopene is not
yet defined; however, 8 mg / day has been recommended by some studies [57].
The cardiovascular benefits of lycopene include its antioxidant and free radical
scavenging activities [58], improved endothelial functions, and LDL reduction
[59].
2.3.4. Omega-3 Fatty Acids
The major dietary sources of omega-3 Fatty acids are fish oil, soya beans, canola
oil, and flaxseed oil. Omega-3 Fatty acids are regarded as essential dietary
components which belong to the polyunsaturated fatty acids (PUFAs) class.
PUFAs are known to possess a multiplicity of beneficial cardio protective actions
and play an important role in both prevention and management of cardiovascular
diseases [30]. Clinical and epidemiological data suggest that omega-3 fatty acids
decrease both the incidence of CAD in healthy humans and complications in
cardiovascular patients [60 - 62].
The mechanisms of the cardiovascular benefits of omega-3 fatty acids include
thromboxane-A2 reduction, decreasing platelet aggregation, improving vascular
and endothelial function through increased nitric oxide production, calcium entry
into vascular smooth muscles inhibition and plasma nor-epinephrine levels
reduction [63].
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2.3.5. Olive Oil
In the Mediterranean diet, olive oil is the major fats source; this diet is related to
the lower cardiovascular disease mortality [64, 65].
Although its beneficial cardiovascular effects are usually linked to
monounsaturated fatty acids (MUFA) high levels, olive oil contains a long list of
natural compounds e.g. phenolic compounds, hydrocarbons, tocopherols, fatty
alcohols, sterols and polar pigments (chlorophylls and pheophytins). Some of
these compounds isolated from olive oil have been shown to improve lipoprotein
metabolism and LDL/HDL ratio [66, 67], ameliorate endothelial function and
nitric oxide production [68], decrease monocyte adhesion [69 - 71], and decrease
oxidative damage and inflammation [72, 73].
2.3.6. Soy
For centuries, soybeans have been employed as food and medicine in Asia [74]. In
a number of epidemiological studies, a cardiovascular protective action of soy
foods has been reported. Soy products reduce the risk of CAD in both men and
women [75 - 77].
The cardio protective actions of soy have been linked to isoflavones, however,
soy contains several classes of bioactive compounds [76, 78]. Isoflavones are
phytoestrogens that protect against atherosclerosis, 38 clinical studies metaanalysis showed that soy proteins consumption significantly improves the blood
lipid profile [79].
2.3.7. Cardiac Glycosides
Cardiac glycosides are produced by several plant species and also found in some
animal venoms. Digoxin and digitoxin, the most well-characterized and
clinically-used cardiac glycosides, have been used for decades as inotropic agents
to treat congestive heart failure.
Digoxin acts by inhibiting the activity of the myocardial Na+/K+ ATPase pump
which leads to Na+ accumulation inside the myocardial cells with subsequent
inhibition of Ca2+ extrusion through the Na+/Ca2+ exchanger [7].
Cardiac glycosides are known for their complex pharmacokinetic profile and low
therapeutic index. In fact, some of the plants containing cardiac glycosides have
been historically used as poisons. Toxicity manifests as ventricular arrhythmias,
heart block, gastrointestinal symptoms [80]. Because these glycosides compete for
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the potassium binding site of the Na+/K+ pump, plasma levels of K+ can be a major
determinant of toxicity. A specific fab antibody is now available for treatment of
digoxin toxicity [81].
3. HYPERTENSION
Hypertension (HTN) is an important risk factor denoting CVD. Globally, about
970 million people are estimated to be suffering from the disease that can
significantly result in morbidity, mortality as well as financial burden. Regardless
to the current developments in pharmaceutical therapy, 53% only reached the
targeted blood pressure [82].
3.1. Pathophysiology of Hypertension
Hypertensive patients are categorized according to the hypertension type whether
primary or essential HTN (95%) or secondary HTN (5%) of hypertensive patients
[83]. The major cause of essential HTN is not yet known, however commences
mostly at the age of 50 - 60 and frequently correlated with high salt consumption
and obesity, in addition to family history, underlining the genetic predisposition
possibility for the disease [83]. On the other hand, secondary hypertension
etiology includes renal artery stenosis, chronic renal disorders and sleep apnea
[83]. Both disorders (primary & secondary) are the import of numerous
mechanisms which are responsible for maintaining normal blood pressures which
are:
3.1.1. Sympathetic Nervous System
Sympathetic nervous system SNS hyperactivity leads to the promotion,
maintenance and development of hypertension HTN. Adrenergic hyperactivity
has been correlated with numerous forms of HTN; systolic-diastolic and isolated
systolic hypertension [84, 85] white- coat hypertension and masked hypertension
[86] as well as dipping, extreme dipping, non-dipping and reverse dipping cases
[87, 88], in addition to, gestational hypertension [89]. Accordingly, sympathetic
nervous system is aggravated in correlation with hypertension conditions [90].
Numerous reports evidenced that hyperactivity of SNS, demonstrated by
norepinephrine increase, extends to patients with HTN approving that the
overactive SNS is one of the major reasons in the pathophysiology of
hypertension. On the other hand, renal sympathetic nervous system is crucial in
the progress and preservation of HTN. It has an impact on blood pressure through
two pathways; the efferent and afferent pathways [82].
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3.1.2. Endothelial Function
There is a solid basis of a clear relation between the endothelial dysfunction grade
and the hypertension severity. The decrease in the nitric oxide level which results
from oxidative stress could be the primary mechanism for endothelial dysfunction
recognized in hypertension. This impaired nitric oxide production could be
resorted by antihypertensive drugs; however, endothelium dependent vasorelaxation alteration may last directly after hypertension is established. Therefore,
endothelium-derived nitric oxide synthase inhibition leads to hypertension in
humans [82]. There are other vaso-relaxing factors alongside with nitric oxide
(NO) for instance, ROS, arachidonic acid metabolites, vaso-active peptides and
endothelial originated micro-particles that are involved in preservation of vascular
tone. The aforementioned factors cause extreme vascular oxidative stress and
inflammation leading to endothelial dysfunction [91, 92]. Thus endothelial
dysfunction could be recognized as massive modifications in the vascular
environment that contributes to structural and functional changes inside the
arteries. Improvement of vascular function by treatments those targeting key
pathways decrease cardiovascular risk.
3.1.3. Renin-angiotensin-aldosterone System (RAAS):
The RAAS is crucial in maintaining normal blood pressures. There are two
mechanisms controlling RAAS; stimulation of the sympathetic nervous system
and glomerular under perfusion [93]. The result of these stimulations is the renin
release from the juxtaglomerular apparatus that alters angiotensinogen into
inactive angiotensin I. Angiotensin I is then converted by endothelium bound
angiotensin converting enzyme (ACE) into angiotensin II, the latter is a potent
vasoconstrictor [94]. Conversion of angiotensin I into angiotensin II occurs in all
tissue and mainly in the lungs. Furthermore, low intake of salt leads to aldosterone
release through RAAS from the adrenal glands which results in reabsorption of
salt and retention of water leading to elevation in blood pressure. Studies revealed
that only 15% of the patients have shown an increase in the plasma renin level,
and it remained normal in 60% and reduced in 25%. Therefore, there is an
acquiescent for the occurrence of local renin systems that regulates the blood flow
that might be correlated to the pathophysiology of HTN [95].
3.1.4. Obesity
Severity of hypertension is extremely conjugated with obesity. Patients recording
30 kg/m2 BMI are liable to uncontrolled systolic blood pressure (SBP) with
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increase 1.5 folds as compared with those less than 25 kg/m2. Another report
evidenced that obese patients recorded high blood pressure as regards to normal
cases. The famous mechanism explaining this phenomenon involved in obesityinduced hypertension is neuro-adrenergic hypothesis in addition to sodium
excretion impairment, fluid retention and the RAAS activation [96].
3.1.5. Vascular Smooth Muscles
The vascular smooth muscle cell invades vascular lumen which initiates increase
in peripheral vascular resistance and consequently development of hypertension
[97]. The whole procedure depends on the interaction between many modulating
factors by either stimulating or inhibiting vascular smooth muscle cell (VSMC)
progression. The fibroblast growth factor (FGF), platelet-derived growth factor
(PDGF), the endothelin-1, the Angiotensin II (Ang II), and the Ca2+- calmodulin
interaction are the prominent causes involved in the vascular remodeling. These
factors control the cross-bridge cycling actin and myosin (Contractile proteins)
[98].
3.1.6. Reactive Oxygen Species
Pathogenesis of hypertension and other vascular complications are clinically
evidenced by excessive production of reactive oxygen species ROS through
different pathologic states. ROS such as hydrogen peroxide (H2O2), superoxide
(O2−) and hydroxyl (OH−) anions, normalize many cellular processes [99, 100].
3.2. Natural Products and Hypertension
Nowadays, herbal drugs have drawn attention for treatment of several ailments as
cardiovascular disorders including hypertension. Due to their safety and
effectiveness herbs and naturals are regarded as an important complement to
conventional therapy. Nevertheless, there are some concerns regarding the use of
herbs, because of the lack of continuous supervision, serious complications and
interactions with other traditional medicines [98].
3.2.1. Nigella sativa (Black Cumin, Black Seed)
Thymoquinone, the key ingredient of the volatile oil of Nigella sativa seeds,
evidenced a decreasing action on BP in humans, as well as, animals [101] studied
the activity of N. sativa seeds oil on lowering blood pressure applying controlled
clinical trial, in seventy healthy subjects of age ranging from 34 - 63 years. The

12 Natural Products in Clinical Trials, Vol. 2

Salem et al.

protocol was designed that randomized subjects were given 2.5 ml seed oil or
placebo twice daily for two months. Results revealed that the oil decreased the
SBP. Another similar clinical study dealt with N. sativa extract at two dose (100
and 200 ml) levels; two times / day for two months, there was also a reduction in
blood pressure [102]. Nigella seed extract exerted also significant reduction in the
total and LDL-cholesterol levels. Interestingly, there were no complications due
to the chronic administration of nigella seeds. Therefore, it was established that
the daily use of nigella seed extract for about two months could lower blood
pressure effect in patients suffering from mild hypertension. The suggested
mechanism for the antihypertensive effects of Nigella sativa was its antioxidant
activity by reducing oxidative stress and also by blocking Ca2+ channels gate
leading to vaso-relaxation.
3.2.2. Beta Vulgaris (Red Beet, Table Beet or Golden Beet)
Beet root is a rich source of dietary NO3- [103] several reports have studied its
potential for regulating blood pressure in humans which was more prominent in
men. A randomized, placebo-controlled study [104], examined the impact of
dietary supplementation of beetroot juice on 68 hypertensive subjects, 34 patients
were treated as control, and 34 treated with age ranging from 18 - 85 years for one
month. Results evidenced that Beetroot intake reduced the blood pressure and
enhanced the endothelial function, together with a reduction in arterial stiffness. It
was also concluded that beetroot supplements were well tolerated with no
tachyphylaxis evidence throughout the treatment. Another crossover study was
conducted on fifteen women and fifteen men. The volunteers received 500 g of
beetroot juice or placebo juice (PL) randomly. The blood pressure was measured
at baseline and each one hour for 24 hours after juice intake using an ambulatory
blood pressure monitor (ABPM). The process was repeated two weeks later.
Results revealed a decrease in the SBP at the sixth hour by 4 - 5 mmHg after
consuming Beetroot juice as compared to placebo juice [105]. The high amount of
inorganic nitrates supplement and the endothelial nitric oxide generation account
for the antihypertensive actions of beetroot juice.
3.2.3. viz Coptis chinensis (Goldthread)
Bebeerine alkaloid (a quaternary ammonium salt) is the major active ingredient of
Coptis chinensis. Bebeerine is reported for the treatment of CVD [106]. The
antihypertensive effects of berberine was reviewed on 228 hypertensive patients.
The hypertensive volunteering patients were randomized to receive bebeerine at a
dose 0.6 g/day in addition to their conventional antihypertensive medications (n =
116) or to control groups receiving antihypertensive medications solely (n = 112).
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Results evidenced that concomitant treatment of bebeerine along with the
antihypertensive medications reduced blood pressure as regards to control group.
The proposed mechanism for bebeerine was claimed to be due to the increased
generation of nitric oxide via NO synthase (eNOS) stimulation and the
catecholamine levels reduction causing peripheral vasodilation and consequently
decreasing blood pressure [107]. Another hypothetical mechanism for the
hypotensive mechanism of bebeerine that the prostaglandin I2 (PGI2) levels are
increased, opening the KATP and blocking the iCa2+voltage gated channels, hence
blocking the Ca2+ cell influx [108].
3.2.4. Hibiscus sabdariffa L.
The blood lowering pressure of Hibiscus sabdariffa L. has been previously
reported and studied on BP-lowering effects have been anthocyanins
(polyphenolic compound) and hibiscus acid is the major constituent in Hibiscus
calyxes and epicalyces are considered the phyto constituents responsible for the
antihypertensive studied in both animals and man [109]. There were no signs of
hepatic or renal toxicity associated with the consumption of Hibiscus extract,
except for probable hepatic side effects at higher doses [110].
A trial [111] was conducted on 65 untreated pre-hypertensive and mildly
hypertensive cases of ages that ranged from 30– 70 years. The protocol involved
randomizing cases to three consumptions daily of 240 ml of either Hibiscus or
placebo for one and a half months. Results evidenced that H. sabdariffa intake
lowered the SBP, however the DBP. Participants recording higher baseline blood
pressure showed more reductions in BP. Furthermore, there was no evidence of
adverse clinical or metabolic effects. It was concluded that Hibiscus tea
consumption may decrease the BP of hypertensive patients due to the NO
increased production, Ca2+ channels inhibition and the KATP channels opening
[112].
3.2.5. Crataegus Monogyna (Hawthorn)
Hawthorn berries are rich in oligomeric procyanidins (leucoanthocyanidins) and
flavonoids that have been employed traditionally for the management of CVD.
Hawthorn extracts evidenced moderate decrease in blood pressure in hypertensive
patients [113]. A cross-over study was performed to investigate Hawthorn
extract’s impact on lowering blood pressure and in flow-mediated vasodilation.
Results showed that there was no significant change from baseline in ABP or in
flow-mediated vasodilation by hawthorn extracts [114]. It was suggested that
Hawthorn extract constitutes bioactive metabolites; procyanidins and flavonoids
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that might increase nitric oxide level and improve endothelial function and hence
exert hypotensive action. Moreover, about 90.5% of the participants
recommended the use of Hawthorn extract in combination with their conventional
antihypertensive drugs.
3.2.6. Allium sativum L. (Garlic)
Garlic is an underground stem (bulb) rich in sulfur compound known as allicin, it
is present in several preparations whether powder or extract. It has been employed
for the management of hyperlipidemia, the prevention of CVD in addition to its
hypotensive effect. A randomized, double-blind, placebo-controlled study [115]
the aged garlic action on uncontrolled was established. In that study eighty-eight
patients suffering from uncontrolled blood pressure received either aged garlic
extract at a dose 1200 mg / day or placebo and Bo was monitored for twelve.
Results evidenced that the blood pressure was significantly reduced with garlic
compared to placebo. Other parameters (central hemodynamic) were measured
indicating an improvement in central BP, central pulse pressure (PP), pulse wave
velocity (PWV), and arterial stiffness as regards to placebo. It was concluded that
garlic significantly reduced the brachial BP and enhanced central hemodynamics,
in addition to its tolerance and acceptance by the patients. Another study
comprising 482 hypertensive subjects was accomplished to track the effect of
garlic on hypertension [116]. The study was conducted from 12 - 26 weeks where
patients consumed garlic preparations at different doses. Results revealed that the
average decrease in BP was significantly lower than placebo [117]. examined the
impact of garlic administration in eighteen trials involving 799 normotensive and
hypertensive subjects. The follow–up was from 3 - 6 months at different dose
levels of garlic administration 300 - 2400 mg/day. It was reported that the BP was
reduced in the hypertensive but not in the normotensive subjects and was better
than that of placebo treatment. The mechanism anticipated for the BP lowering
effect of garlic was correlated the sulfur compounds- allicin the most importantwhich are reputed for modulating endothelium-relaxing factors; stimulation for
No production and hydrogen sulfide (H2S), also allicin causes ACE inhibition and
hence BP was reduced [115].
3.2.7. Crocus sativus L. (Saffron)
Saffron is rich in interesting bioactive metabolites as safranal, crocetin, crocin and
picrocrocin, flavonoids and anthocyanins that exert antihypertensive and
vasodilatory effects [118]. A randomized, placebo-controlled study was
performed in thirty volunteers to clinically prove the BP-lowering effects of
Crocus sativus [119]. Study design was achieved by dividing the subjects into
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three groups (10 per group) and blood pressure was monitored for one week.
Results evidenced significant decrease in SBP 11 mmHg and lowering arterial
pressure 5 mmHg at dose level 400-mg of the herb. The mechanism of action for
the antihypertensive and vasodilatory action of C. sativus suggested in this study
was mediated via Ca2+ channels blockade, K+ channels opening and βadrenoceptor antagonism.
3.2.8. Panax ginseng (Ginseng)
Panax ginseng (F. Araliacea) roots have been reputed in folk medicine for
different disorders including cardiovascular disorders and hypertension.
Triterpenoidal and steroidal saponins are the major bioactive ingredients of
ginseng responsible for its CV effects. Clinical trials evidenced a significant
decrease in blood pressure. American ginseng (AG) effects on arterial stiffness
and BP reduction was revised in a randomized study [120]. The study was
pursued in 64 hypertensive diabetic patients aging 63 ± 9.3 years for 12 weeks.
Results revealed a reduction in BP, the augmentation index (AIx)and the pulse
pressure (PP). Another randomized, double-blind, cross-over [121] investigated
the Korean red ginseng effects on BP and arterial stiffness in twenty three
normotensive samples aging 25 ± 2 years. The extract exhibited statisticallysignificant reductions in AIx, central SBP, central DBP and brachial BP, three
hours after intervention as compared to the control. The effects of P. ginseng
extracton BP was further studied in ninety subjects with the age range of 55.2 ±
11.8 years and BP range of 120 - 159/80 - 99 mmHg and the follow-up was for
two months [122]. Results showed that the seated SBP (sSBP) and DBP (sDBP)
levels were decreased only upon the administration of high dose at the fourth
week. Unlikely, at the eighth week, there was a decline in the differences between
the groups. Moreover, no significant metabolic or clinical side effects were
reported. The effects of P. ginsengon BP reduction were mainly accredited to its
vascular effects intermediated by a massive eNOS expression increase and NO
production increase, in addition to, Ca2+ channels blockade [120, 123].
3.2.9. Camelia sinensis L. (Tea Plant, Tea Shrub)
Camellia sinensis L. (Family Theaeceae) (leaves and leaf buds) is the most
commonly consumed beverage worldwide and are the most frequently consumed
beverages worldwide. Tea leaves have diverse biological activities; antiinflammatory, antidiabetic, and antihypertensive actions. Many studies have
demonstrated significant antihypertensive action. In a trial by [124], where 95
hypertensive patients in the age ranging from 35 to 75 years under took the study.
The BP follow-up duration was for six months. Results were in good agreement
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where the arterial blood pressure (ABP)measured through 24 hours was reduced
in the group receiving tea as compared to the placebo group. Another report on
the effect of black and green tea to reduce blood pressure [125]. Eleven trials were
revised; 7 consumed green tea and 4 received black tea in 821 subjects for 6
months. It was deduced that the green tea caused more reduction in BP compared
to black tea. There were no adverse reactions and was well tolerated treatment as
well. On analyzing the mechanism of action of both black and green tea in
reducing blood pressure, the major action is supposed to be due to its
polyphenolic content mainly catechins. Catechin is a flavan-3-ol with powerful
antioxidant activity that stimulates nitric oxide production and reduces
endothelin-1concentrations in the plasma. These actions collectively lead to a
decrease in vascular tonicity leading to vasodilatation and peripheral vascular
resistance reduction and BP reduction.
3.2.10. Cymbopogon citratus (Lemongrass)
Citral the active ingredient of the volatile oil of Lemongrass has been used in the
management of hypertension due its vasodilating action. Lemon grass proved in a
hypertensive rat model its effect to reduce blood pressure [126]. This was
correlated to its vaso-relaxant and antioxidant effect [127].
3.2.10. Peumus boldus (Family Monimiaceae)
is an aromatic and evergreen shrub, where the leaves are the most common part
used due to its boldine content. Boldine is an alkaloid of the aporphine class with
potent antioxidant activity. The effects of boldine on endothelial dysfunction were
evaluated in spontaneously hypertensive rats (SHR). The study used SHR versus
their age-equivalent normotensive rat for one week. Results revealed that control
group of SHR demonstrated SBP elevation, endothelium-dependent aortic
relaxation to acetylcholine reduction, endothelium-independent aortic relaxation
to sodium nitroprusside attenuation, aortic superoxide increase and peroxynitrite
production, and p47 protein expression enhancement as regards to control rats. In
conclusion, boldine possesses endothelial protective action in hypertension via
NADPH-mediated superoxide production inhibition [128, 129].
4. ANGINA PECTORIS
Angina, known as angina pectoris/angina cordis / angor pectoris / RougnonHeberden disease, is a well-known cardiovascular disorder which is frequently
associated with coronary heart diseases. The term “angina pectoris” was first
introduced in 1772 by William Heberden [130]. It occurs due to the failure of the
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coronary blood supply to meet the myocardial oxygen demands. Basically, this
failure is a result of coronary obstructions in which the atherosclerosis restricts the
blood flow to the heart muscle forming a fixed obstruction. Sometimes this
obstruction is dynamic due to coronary spasms or even patients with mixed
angina may have both kinds of obstruction. Other causes extend to include
anemia, arrhythmia and heart failure [131 - 133].
Globally, CAD is the major cause of mortality, accounting for about 7.2 million
deaths annually [134]. The prognosis of angina depends predominantly on the
quantity of obstructed vessels and the obstruction extent. The risk of vasospasm
and thrombosis is significantly increased in cases of 80% or more vessels
obstruction. A twelve-year survival rate is estimated to be 88%, 74%, 59%, and
40% for subjects having zero, one, two, and three-vessel disease respectively.
This estimated survival rate could be affected by other factors such as congestive
heart failure, ejection fraction, previous myocardial infarction, diabetes, age and
smoking history. It could be concluded that, patient prognosis remarkably varies
by up to 10 folds according to several parameters as clinical, anatomical and
functional factors [135, 136].
The diagnostic tools employed for angina are clinical manifestations, laboratory
tests and other invasive and non-invasive cardiac investigations. These tools are
usually used for both diagnostic and prognostic evaluations which are done
randomly. The history of the patient is considered the foundation of angina
diagnosis; hence, confident diagnosis could be based solely on it [136].
Angina patients suffer from paroxysmal thoracic pain with a heavy strangulation
or pressure-like sensation that radiates to the left arm, jaw, epigastrium, back and
shoulder as explained by referred pain. This pain is usually accompanied by
suffocation feeling, shortness of breath, tiredness, sweating, dizziness, sometimes
nausea, tachycardia and hypertension [137].
The chest pain in angina patients should be described in regards to its location,
duration, character and its relation to exertion to prevent any confusion with other
cardiovascular diseases [136]. Angina should not be confused with heart attacks,
where in case of angina the blood flow restrictions are related to physical exercise,
temporary and does not cause damage or destruction to the heart muscles.
However, angina patients are at higher risk of having heart attacks and its
complications [133].
Laboratory tests for angina includes tests undertaken to (a) Determine the causes
of ischemia, such as hemoglobin and thyroid hormones (if susceptible thyroid
disorder), also, markers of myocardial injuries as Creatinine Kinase Myocardial
Band (CKMB) could be used to exclude myocardial damage if required clinically.
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(b) Evaluate cardiovascular risk factors, for example, fasting blood glucose,
glycated hemoglobin, serum creatinine and total lipid profile and furthermore,
cholesterol subfractions (Apo A and Apo B), homocysteine, lipoprotein a (Lpa),
and hemostatic abnormalities, inflammatory markers (hs-C-reactive protein) and
NT-BNP are used as predictors of long-term risk factors. (c) Evaluate the
prognosis, such as complete blood count including WBCs count. However, the
laboratory tests used for initial diagnosis and routine reassessment are
controversial and variable according to the case evaluated [136].
Non-invasive investigations include the regular resting Electrocardiography
(ECG); ECG stress testing, stress testing (with imaging), echocardiography (at
rest) and ambulatory ECG monitoring. In addition, coronary calcification and
coronary anatomy assessments such as computed tomography (CT) scans and
Magnetic Resonance (MR) arteriography may be used as non-invasive diagnostic
tools for angina. Invasive investigations are used to ascertain the diagnosis or
treatment options [136].
There are four major classes of angina;
(a) Stable angina: It is characterized by chest pain and associated symptoms that
are precipitated by physical activity, cold weather, heavy metals, excitement or
emotional stress. These symptoms subside at rest or upon treatment with
nitroglycerin. Hence, this type of angina is the classical type and referred to as
effort angina [138]. Stable angina is regarded as the most common manifestation
of myocardial infarction [139].
(b) Unstable angina: It is defined as the worsening of angina, in which the chest
pain occurs with sudden-onset at rest or minimal exercise and lasts for more than
ten minutes, becomes more severe and more frequent. This type of angina is
referred to as crescendo angina as it occurs with a crescendo pattern i.e.
prolonged, more severe and more frequent [131].
(c) Prinzmetal angina: It is similar to the unstable angina in which the patients
suffer from severe pain that usually occurs while resting or sleeping; however, it
arises from transient increase in coronary vascular tone (vasospasm). It is also
known as variant or vasospastic angina [140].
(d) Microvascular angina: It was historically known as cardiac syndrome X,
characterized by angina-like chest pain [141]. Studies consider this type of angina
a part of the pathophysiology of ischaemic heart disease that is more common in
women [142, 143]. It does not show major arterial blockages however it is
suggested to result from endothelial dysfunction and reduced flow in the microblood vessels of the heart [144].
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The major risk factors of angina are the age factor (men over forty-five years and
women over 55 years), smoking, Diabetes mellitus, hypercholesterolemia,
hypertension, renal diseases, obesity (body mass index exceeding 30), family
history of premature cardiovascular diseases, sedentary lifestyle and emotional
stress [145].
The patient age is paramount to the prevalence of angina, as it increases from 0.1 1% to 10 - 15% as for 45-54 years old women to 65 - 74 years old women
respectively, similarly, it increases form 2 - 5% to 10 - 20% as for 45 - 54 years
old men to 65 - 74 years old men respectively. Fortunately, there is a pragmatic
decline in the incidence rate of angina in the recent decades [136].
4.1. Pathophysiology of Angina Pectoris
The imbalance between the oxygen supply to the heart and its demand will evoke
angina. This imbalance could arise from exercise, for example, in which there is
an increase in the demand for oxygen and in cases of atherosclerosis or coronary
arteries obstruction there will not be a sufficient oxygen supply. The myocardial
oxygen demands vary according to the heart rate, heart muscle contractility and
most importantly, the intra-myocardial wall tension. The myocardial oxygen
supply is affected by the difference of arteriovenous oxygen pressure and the
coronary blood flow [139]. This blood flow may be radically altered by
atherosclerotic plaque which will result in an imbalance in case of increased
myocardial oxygen demand. In most cases, the pathophysiological substrate of
angina is atheromatous, nevertheless, it varies according to the patient's gender,
whereas; women usually suffer from non-obstructive coronary disease type of
angina [136, 146, 147].
Conventional treatment of angina is primarily aiming to relieve its symptoms,
slow its progression and prevent its long-term complications as decreasing the
risks of its development to heart attacks or even mortality. Different treatment
pathways are depicted in Fig. (1). These treatments comprise the use of
vasodilators, mainly nitroglycerin (used sublingual for acute cases with short
duration, oral for intermediate duration cases and transdermal for longer
durations) [148]. Caution should be taken with patients taking a
phosphodiesterase (PDE5) inhibitor, as sildenafil, as it is contraindicated with any
form of nitrates causing sudden decrease in the blood pressure. Other vasodilators
used for treatment of angina include Ca2+ channel blockers, β- blockers and ACE
inhibitors in which their mechanisms of action involve decreasing the heart work
load which will decrease the myocardial oxygen demand or increase the coronary
blood flow resulting in myocardial oxygen supply increase. Both mechanisms will
in turn reverse the case of imbalance between the oxygen supply and demand
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[136, 149]. Cyto-protective medications such as trimetazidine, are usually used as
antianginal agents to increase the cell tolerance to ischemia by maintaining
cellular homeostasis [150]. Recently, new classes has been used in the treatment
of angina, for example If inhibitors (Ivabradine), which act by decreasing the
heart rate with major anti-ischaemic and antianginal efficacy [151] and potassium
channel openers (Nicorandil).

Fig. (1). Different treatments for angina pectoris [136, 148 - 158].

In 1990, the FDA approved bepridil as an antianginal agent having direct negative
chronotropic, ionotropic and vasodilator effects. It differs from calcium channel
blockers in which it causes the inhibition of receptor-operated, voltage-gated Ca2+
channels as well as K+ currents and intracellular Ca2+/calmodulin complexes
[152]. Also, ranolazine was recently approved as a treatment of angina either as a
replacement of beta blockers or as a complementary therapy with them. It acts by
inhibiting the late sodium current, therefore reducing intracellular Na+ and Ca2+
accumulation which in turn increases oxygen supply and reduces oxygen demand
[153]. In addition, anti-hypercholesterolimics as statins, could be used to stabilize
the atheromatous plaque and reduce the regression of coronary atherosclerosis
[154]. Although, classically the administration of antiplatelets such as low doses
of aspirin was a standard treatment for angina along with the vasodilators, it is
now restricted to cases of high risk of myocardial infarction as it was found to
cause hemorrhagic stroke and gastrointestinal bleeding [155].
Invasive treatment of angina (Revascularization) includes Percutaneous Coronary
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Intervention (PCI), where a catheter enclosing a balloon enters to the arterial
lumen then inflates to cause lumen widening; it is usually accompanied with
stents to maintain the widening effect. Also, coronary-artery bypass surgeries
(CABG) may be employed where venous grafts are used to bypass the constricted
arteries. Revascularization is basically performed to relieve the angina symptoms
yet it also has a prognostic benefit for patients who are at high risk [156].
Cell-based therapies for ischemic cardiomyopathy are still in its preclinical phases
questioning its efficacy and feasibility. Experimentally, it was found that induced
pluripotent stem cells and embryonic stem cells have regenerative abilities and
cause cardiac function improvement after ischemia [152]. However, novel
treatment modalities, for example coronary sinus reducers, cell-based therapies,
gene and protein therapies, are still under evaluation [157].
Other management procedures could be used for the control of angina such as;
gentle long-term exercise aiming to improve the blood pressure and promote the
collateralization of the coronary arteries. In addition to, the control of lipid profile,
blood pressure, diabetes and weight, quitting smoking and avoiding psychological
stress [158].
4.2. Natural Products and Angina Pectoris
The evidence-based therapy of cardiovascular diseases by natural products is
controversial. In fact, the use of botanicals in the treatment of angina is
questionable as it may not cause relieving of the angina symptoms directly, which
is the chief goal of the treatment as fore-mentioned. However, these natural
products may be employed as secondary treatments for cardiovascular diseases
[159]. Table 1 represents the key individual botanicals employed in the
management of angina pectoris, it includes parts used, major active ingredients,
the designs of different experiments that reported their activity and their
mechanisms of action.
Key botanicals used in the treatment of angina includes Hawthorn (Crataegus
oxyacantha, C. monogyna, C. laevigata, and C. pinnatifida) [159, 160], Danshen
(Salvia miltiorrhizae) [159], San qi (Panax notoginseng) [159], Garlic (Allium
sativum) [159], Gingko biloba [159, 161], Arjuna (Terminalia arjuna) [159, 160],
Pushkarmoola (Inula racemose) [159, 160, 162], Turmeric (Curcuma longa)
[159], Ligusticum chuanxiong Hort [159]. Guggul (Commiphora mukul) [160],
Gualoupi (Trichosanthis kirilowii or T. rosthornii) [163].
Other natural products that could be used as antianginal agents are; grapes, as it
has been proposed that resveratrol is an antiaging metabolite and prevents the
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decline in cardiovascular function caused by aging through the expression of
several longevity genes [164]. Coleus contains the alkaloid forskolin, exhibits
hypotensive, positive inotrophic, vasodilator, anti-platelet aggregation activities
[165]. Khellin, from khella, was reported to have more potent action than many of
the common coronary vasodilators [166]. Also, Alfalfa leaves, sprouts, ginger,
green tea, lingzhi and brindle berry were found to possess hypolipidimic
activities, through which they have potential antiatherosclerotic effects [167].
A step further was undertaken to evaluate the beneficial effects of single
compounds in the treatment of angina. However, most of these compounds were
assessed as an approach to avert its long-term complications, with exception to
puerarin, a well-established antianginal agent. It is an isoflavone purified from
Pueraria genus, which significantly reduces the frequency of angina events and
myocardial oxygen consumption, increases the duration of exercise and reverses
the abnormal rest ECG in a clinical study involving unstable angina patients
[168].
Table 1. Key botanicals used in the treatment of stable angina pectoris.
Plant

Part Used

Hawthorn
Leaves,
(Crataegus
flowers, and
oxyacantha), berries
(C.
monogyna),
(C. laevigata),
and (C.
pinnatifida)

Main Active
Constituents

Experimental
Design

Mechanism of Action

Oligomeric
proanthocyanidin

Randomized
controlled trials,
observational
cohort study,
multicenter,
placebo-controlled,
double-blind study
and In vitro studies

● Increases the force of
myocardial contraction ●
Enhances coronary blood
flow and coronary
perfusion ● Improves
oxygen utilization by
cardiomyocytes ●
Prolonges the refractory
period and action-potential
duration in heart and
papillary muscles ● Has a
mild hypotensive effect ●
Antagonizes atherogenesis
with a negative
chronotropic effect and a
positive inotropic effect on
the contraction amplitude
of cardiac myocytes ●
Inhibits 3′,5′-cyclic
adenosine monophosphate
phosphodiesterase ●
Lowers arrhythmogenic
risk as it prolongs the
effective refractory period
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Plant

Part Used

Main Active
Constituents

Experimental
Design

Danshen
Salvia
miltiorrhizae

Root

Tanshinone (I, IIA, and Animal studies, In
IIB) and salvianolic
vitro studies and
acids (A, B)
randomized
controlled trials

Mechanism of Action
● Enhances the recovery of
contractile force upon
reoxygenation following
myocardial ischemia ●
Reduces ischemic
symptoms and improves
the pathological
electrocardiogram (ECG)
pattern ● Has a negative
inotropic effect and
increases the coronary flow
rate ● Can reduce the
infarct size caused by
myocardial ischemia ●
Reduces the risk of
myocardial tissue necrosis.
● Upregulates the
expression of vascular
endothelial growth factors
● Improves
microcirculation, causes
endothelium-dependent
vasodilation in aortic strips,
causes general vasodilation
(low dose) and
vasoconstriction in
noncoronary arteries (high
dose) ● Inhibits
angiotensin-converting
enzyme ● Increases nitric
oxide production by
endothelial cells. ● Inhibits
thrombosis, thromboxane
B2 formation, and platelet
aggregration ● Antioxidant
activity
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Main Active
Constituents

Experimental
Design

Mechanism of Action

San qi Panax Root
notoginseng

Saponines
(ginsenosides) and
notoginsenosides

Animal studies, In
vitro studies

● Reduces myocardial
oxygen consumption and
protects the myocardium ●
Increase coronary blood
flow ● Enhances blood
fibrinolytic parameters ●
Dilates coronary arteries
(dose dependent) ● Inhibits
atherosclerosis by
inhibiting the proliferation
of aortic smooth muscle
cells ● Reduces
thrombogenicity and
increases erythrocyte
deformability. ●
Suppresses cardiac
arrhythmias during
oxygen-deprivation
ischemia and reperfusion ●
Calcium ion channel
antagonist in vascular
tissues, resulting in
hypotension ● Lipidlowering effects and
antioxidant activity

Garlic Allium Bulbs
sativum

Garlicin

Randomized
controlled trials,
double-blind,
crossover study and
In vitro studies

● Inhibits platelet
aggregation ●
Hypolipidemic action ●
Enhances the fibrinolytic
activity ● Protects the
elastic properties of the
aorta ● Hypoglycemic
action

Maidenhair
Leaves
Gingko biloba

Ginkgolides, flavonoid
glycosides, terpene
lactones and ginkgolic
acid

Animal models, and ● Inhibits the plateletclinical trials
activating factor ●
Antioxidant activity ●
Increases the blood flow
via release of nitric oxide
and prostaglandins

Arjuna
Terminalia
arjuna

Triterpinoids,
flavonoids, and
minerals

Animal models,
double-blind
crossover study,
open-label studies
and randomized
controlled trials

Stem bark

● Positive inotropic ●
Vasodilator effect on
coronary arteries ●
Reverses smoking-related
endothelial dysfunction ●
Lipid-lowering effects and
antioxidant activity
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Main Active
Constituents

Experimental
Design

Mechanism of Action

Pushkarmoola Root
Inula
racemosa

Sesquiterpene lactones
(alantolactone and
isoalantolactone)

Animal studies,
preliminary clinical
study, open-label
clinical study

● Negative ionotropic and
negative chronotropic
effect ● Blocks the action
of adrenaline ● Act as an
agonist for propranolol ●
Improves hemodynamic
function and leftventricular function ●
Antioxidant activity

Turmeric
Curcuma
longa

Rhizome

Curcuminoids
Animal studies,
demethoxycurcumin
randomized
(curcumin II),
controlled trials
bisdemethoxycurcumin
(curcumin III), and
cyclocurcumin

● Antioxidant effects that
attenuate adriamycininduced cardiotoxicity ●
Prevents cardiovascular
complications associated
with diabetes ● Inhibit
p300-HAT and thus can
ameloriate the development
of cardiac hypertrophy and
heart failure ●
Antiinflammatory effects
may prevent atrial
arrhythmias ● Lipid
lowering effects

Ligusticum
chuanxiong
Hort .

Root

Phalides (senkyunolide,
Z-ligustilide,
ligustiliden, ligustilide
dimers, ligustrazine
neocnidilide, 3butylphthalide,
Butylidenephthalide,
and
Tetramethylpyrazine )

In vitro studies,
controlled and selfcrossover clinical
trial

● Relaxes the vascular
rings and inhibits against
contractions induced by
phenylephrine; the
potentiation of relaxation is
postulated to be related to
nitric oxide ● Increases
coronary blood flow and
decreases myocardial
contractile force ● Inhibits
the TNF-alpha production
and TNF-alpha bioactivity
in human monocytic cell
lines

Guggul
Commiphora
mukul

Oleo-gum-resin Guggulipid and
guggulsterones

Animal studies,
double-blind
placebo control
study

● It is an antagonist ligand
for the bile acid receptor
(farnesoid X receptor)
which causes
hypolipidemia ● Increases
the plasma fibrinolytic
activity
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Part Used

Main Active
Constituents

Gualoupi
Pericarp of ripe Lignan,
Trichosanthis fruits
trichobenzolignan and
kirilowii or T.
trichosanthin
rosthornii

Salem et al.
Experimental
Design

Mechanism of Action

Animal studies,
randomized
controlled trials

● Regulates lipid
metabolism, exerts
antiatherosclerotic effects
and protects the vascular
endothelium. ● Protects
against ischemia
reperfusion, injury,
hypoxia, and calcium
antagonism

Its mechanism of action involves the preservation of the mitochondrial structure
and decreasing the myocardial lactate production and creatine phosphokinase
release following a myocardial injury in a dog model [169]. Another clinical study
proved that puerarinis involved in regulating endothelin, rennin, and angiotensin
II imbalance in acute myocardial infarction patients [170]. Nevertheless, another
clinical study suggested an alternative mechanism of action of puerarin involving
platelet activating factors in patients with unstable angia pectoris [171].
Tetrahydropalmatine, an isoquinoline alkaloid isolated from Corydalis genus and
Stephania rotunda, was reported to treat the increase of creatine kinase and
aspartate aminotransferase in a rat model [172]. Magnesium tanshinoate B
isolated from Salvia miltiorrhizae was found to stimulate NO release, enhance the
cellular activities of NO synthase and associated increase the levels of constitutive
NO in human endothelial cells in vitro [173]. Scutellarin, the major constituent of
Erigeron breviscapus, decreased the degree of MI induced by isoprenaline in rats
as proved recently by Huang et al. [174] Similarly, Baicalin from the genus
Scutellaria, possesses protective actions on MI in rats. The probable mechanisms
may involve its resistance to oxidative stress, and up-regulation of B-cell
lymphoma-2 (Bcl-2) protein expression and down-regulation of Bcl-2 associated
X (Bax) protein expression in myocardial tissue [175]. Also, the
benzylisoquinoline alkaloid, berberine, significantly reduced the release of
creatine phosphokinase and reversed the ultrastructural damage in isolated rat
hearts [176], berberine’s positive inotropic effect and mild vasodilation action
helps its amelioration of the impaired left ventricular function and the decreased
cardiac output in dogs [177, 178].
In conclusion, the mechanisms of action of most of these natural products need
further clarifications and there is insufficient basis of their effectiveness in the
treatment of various CVD. Hence, it is a need rather than an interest, to pay more
attention to confirm the traditional claims of their use as antianginal agents.
Multidisciplinary research is very important to evaluate the therapeutic potential
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of these natural plants and point out the active constituent(s) responsible for the
activity and its/their effective dose, through biologically guided studies. In
addition to, their possible synergistic interactions with each other or other
antianginal drugs and their adverse side effects. This will aid in their
establishment as antianginal agents and their addition to the mainstream of
cardiovascular remedies.
5. ATHEROSCLEROSIS
5.1. Pathophysiology of Atherosclerosis
Atherosclerosis is the key cause for the development of various CVD such as
angina, myocardial infarction and ischemic heart failure. Atherosclerosis is
characterized by endothelial dysfunction, inflammatory responses, extracellular
matrix alteration, Smooth Muscle Cell (SMC) proliferation and thrombosis [179].
Atherosclerosis development may lead to blood supply reduction to the coronary
arteries which can cause MI, which is the main pathological factor for coronary
heart diseases [180].
Large and middle-sized arteries intima are particularly the sites of arterial
bifurcations and they are highly influenced by atherosclerosis. Vascular SMCs,
WBCs and modified lipids are accumulated in the intima. The accumulated SMCs
at the tunica intima layer of the arteries can then migrate to form atheroma plaque
through their proliferation. Pro-inflammatory activation of vascular SMCs causes
a change to synthetic from contractile phenotype, leading to cell proliferation and
migration. This migration of the activated vascular SMCs from the media to the
intima leads to pro-atherosclerotic vascular remodelling [181].
The matrix metalloproteinases (MMPs), are involved in the process of
proliferation and migration of vascular SMCs as it has a proteolytic activity that
allows it to cause elastic lamina barrier of extracellular matrix degradation leading
to various pathological conditions [182, 183].
In addition, these arterial regions suffer a turbulent shear stress that promotes
endothelial cells (ECs) pro-inflammatory activation [184]. This activation is
stimulated by the modified LDL, especially the oxidized LDL (oxLDL). The
activated ECs express intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule (VCAM-1) which attract monocytes and lymphocytes
binding the endothelium and infiltrate the intima. Also accumulation of oxLDL
takes place in the sub-endothelial level developing the atheorosclerotic plaque. In
the intima, monocytes differentiate to macrophages which engulf oxLDL deposits
and transform into foam cells [185]. Other immune cells are present in the lesion
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and are involved in the intraplaque inflammation [186]. During the progression of
atherosclerosis, immune and non-immune vascular cells release a variety of proinflammatory messengers that preserve and improve the local inflammation and
atherosclerotic lesions development) Fig. (2). Also, the concomitant up-regulation
of pro-inflammatory signalling pathways in both vascular and blood cells
stimulates atherogenesis [187].

Fig. (2). Schematic representation of the mechanism of atherosclerosis.

There is increasing evidence that NO and NO synthase (NOS) systems in vascular
SMCs can regulate the local vascular injury accompanying atherosclerosis. In
healthy vessels, endothelial isoform of NOS (eNOS) produces NO in the
endothelium and acts as an endothelium-derived relaxing factor essential for
maintenance of vascular homeostasis. In atherosclerotic vessels, the endotheliumdependent relaxation impaired and represents the reduced eNOS-derived NO
bioavailability that promotes atherosclerosis development [187]. In case of
atherosclerosis, the inducible isoform of NOS (iNOS) is unable to recompense for
the lost functional endothelium and eNOS [188]. Increased expression of iNOS
has been linked to stimulating the pathogenesis of atherosclerosis [189]. In the
advanced atherosclerotic plaques, iNOS may constantly indorse a pathogenic
environment via oxidative and nitrosative stress enhancements [190]. There are
much evidences that foresees the NO and NOS system as a potential target for
atherosclerosis management.
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5.2. Natural Products and Atherosclerosis
5.2.1. Ginkgetin
Medicinal plants have proven great efficacy as therapeutic agents for
atherosclerosis. G. biloba is a plant of family Ginkgocea whose leaves have high
content of acylatedflavonols, bioflavonoids and terpenoids [191]. Among Ginkgo
biflavones, ginkgetin 3) Fig. (3) has been shown to possess anti-inflammatory,
neuroprotective, and anti-cancer activities [192]. Ginkgetin has been reported to
down-regulate the expression of the matrix metalloproteinase (MMP-2 and MMP9) in thoracic aortas of atherosclerotic rats [193]. As mentioned before, MMPs
have a primary role in enhancing vascular remodeling and SMC migration [194].
Various matrix cells and macrophages produce MMP-9 which contributes in the
degradation process of active substance in extracellular matrix of various tissues
[195]. Thus, reduction in MMPs expression helps the remodeling of vascular
extracellular matrices and reduces the migration of SMCs, thus contributes to the
improvement of atherosclerotic rats.

Fig. (3). Structure of Ginkgetin.

NO can suppress the progression of atherosclerosis by decreasing monocyteendothelial cell interaction, hindering the adherence and aggregation of the
platelets, and thus prevent SMC proliferation. Moreover, in the atherosclerotic
rats, the expression of eNOS in serum and thoracic aortas was notably reduced,
indicating that absence of NO promotes the pathogenesis of atherosclerosis [193].
Ginkgetin could increase the levels of NO in atherosclerotic rats. Ginkgetin was
also found to up-regulate the levels of eNOS expression and down-regulate the
levels of iNOS expression which were elevated atherosclerotic rats [193]. The
increased expression and activity of iNOS was linked to the progression of
atherosclerosis that was induced in vascular SMCs by pro-inflammatory cytokines
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released from injured cells [190]. Thus that ginkgetin can be said to ameliorate
atherosclerosis through modulation of NO/NOS system.
5.2.2. Colchicine
Colchicine as shown in Fig. (4) is a tropolone alkaloid isolated from the seeds and
corms of genus Colchicum. Now, Colchicine is used for relieving the pain
resulting from gout or familial Mediterranean fever, and under research to be used
for treatment of pericarditis, and Behçet's disease due to its anti-inflammatory
activity but its clinical applications is still limited due to its toxicity [196 - 198].
Anti-inflammatory activity of colchicine through which it inhibits inflammation in
patients with acute coronary syndrome (ACS) or after acute MI is mediated by its
anti-tubulin action and neutrophil function inhibition [199].
In a clinical trial, administration of oral dose (1 mg) of colchicine daily for 4
weeks has caused reduction in CRP levels in patients suffering from CAD [200].
In another clinical trial conducted on larger sample (532 of CAD patients), a daily
dose of colchicine (0.5 mg) for 30 days caused a three-fold reduction of incidence
cardiac arrest and non-embolic stroke and this effect last during the median threeyear follow-up period [201].
In a prospective non-randomized pilot study conducted on 80 subjects with recent
post-acute coronary syndrome (ACS) that last for less than one month, patients
received either 0.5 mg/day colchicine plus optimal medical therapy (OMT) or
OMT alone and with a followed up over a year. The results of this pilot study
showed that colchicine at low dose caused modification of the coronary plaque,
independent of high-dose statin combined therapy and significantly reduced the
low-density lipoprotein (LDL). Colchicine also improved the plaque morphology
through its anti-inflammatory effect which also helped in the reduction of highsensitivity C-reactive protein (hsCRP), rather than changes in lipoproteins [202].
A review of 4992 patients in thirty nine trials of any clinical setting involving
long-term colchicine compared to control showed that colchicine proved no effect
on heart failure and stroke, however it showed efficacy in populations suffering
Myocardial Infarction (MI) at high-risk [203]. Administration of colchicine for
more than 6 months showed potential efficacy in minimizing MI risk and
cardiovascular mortality [204].
A study was conducted on 1288 subjects having gout, and at high cardiovascular
risk, in which the administration of colchicine caused a fifty four percent
reduction in relative risk of MI [205]. Another retrospective cohort study
investigated 501 gout patients and similar protective effects of colchicine were
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observed [206].
Another trial was performed on 196 patients suffering from diabetes mellitus who
had percutaneous coronary intervention with a bare metal stent. Administration of
Colchicine for six months exerted a decrease in in-stent restenosis relative to
placebo as shown in the follow-up angiography and intravascular ultrasound
[207]. However, another double blinded, placebo-controlled study of 145 patients
using the same dose of colchicine did not show improvement in the rate of
angiographic restenosis in elective coronary angioplasty of 393 lesions without
stent placement [208].
Furthermore, the role of colchicine was assessed specifically in a randomized trial
conducted on 151 patients with ST-segment elevation MI (STEMI) who received
colchicine for five days. Colchicine treated group showed a significant lower
infarct size, as evaluated by creatine kinase-muscle/brain (CK-MB) concentration
when compared to the placebo group. The cardiac magnetic resonance imaging of
60 of these patients confirmed that colchicine could significantly reduce the
infarct size when compared to the left ventricular myocardial volume [209].

Fig. (4). Structure of Colchicine.

5.2.3. Garlic
Garlic (Allium sativum) contains active ingredients which exert prophylactic and
treating effects against atherosclerosis [210].
A garlic-based herbal preparation was prepared and named Allicor. This
preparation was tested in a pilot study which included 28 healthy men with the
age range of 46–58 (52.0 ± 9.0). Anti-atherosclerotic activity of the preparation
was indicated by the carotid intima-media thickness (cIMT), the subjects received
Allicor daily for total duration of a year, however, ultrasound examination of the
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carotid arteries were held every 3 months. The product was well-tolerated that
was deduced from the absence of the adverse effects during the follow-up period.
Allicor significantly reduced the tendency to cIMT [210].
In a clinical study, the effect of Allicor on the cIMT progression in 211
asymptomatic men aged 40 - 74 was studied. By the end of the first year followup period, a significant reduction of cIMT was observed in the Allicor-treated
group, when compared to the placebo group [211]. After the 2-years follow-up
period, the mean rate of cIMT was significantly reduced in the Allicor-treated
group, relative to the placebo group [212, 213]. Consequently, it was recorded
that long-term treatment with Allicor possessed an anti-atherosclerotic effect
which was attributable to the improvement of serum atherogenicity [212, 213].
5.2.4. Anti-inflammatory Herbs
Inflammation has a crucial role in all the development stages of atherosclerosis
[214, 215]. Many anti-inflammatory plants of the Mediterranean region can be
used for the protection against atherosclerosis. Therefore, Calendula (Calendula
officinalis), elder (Sambucus nigra) and violet (Viola tricolor) have been reported
to have both anti-inflammatory and anti-atherogenic effects [216, 217]. Inflaminat
is a combination of the three above mentioned plants, its effect was evaluated on
cIMT in a pilot phase of a study designed on 67 asymptomatic men for a year
[213, 218, 219]. In subclinical atherosclerosis, inflaminat could induce cIMT
regression, which was significant relative to the placebo group. Thus, Inflaminat
demonstrated anti-inflammatory and anti-atherosclerotic effects on cellular levels
and induced regression of subclinical atherosclerosis in asymptomatic men.
5.2.5. Phytoestrogen-rich Herbs
Several natural herbs that are rich in phytoestrogen, showed promising in vitro
and ex vivo anti-atherogenic activity were incorporated into an herbal preparation
named Karinat [220 - 222]. These herbs are garlic powder, extract of grape seeds
(Vitis vinifera), green tea leaves (Camellia sinensis) and hops (Humulus lupulus).
Additionally, Karinat was rich in biologically active polyphenols including
resveratrol, genistein and daidzein, thus it could improve phytoestrogen profile.
Karinat was tested for anti-atherosclerotic effect in a pilot clinical study on 157
asymptomatic postmenopausal women for a year [223, 224]. At the end, an
increase in the mean cIMT was detected in the placebo group, with a 40% growth
in the atherosclerotic plaque in postmenopausal women. Inversely, the mean
cIMT remained stable in the Karinat-treated group. The studied phytoestrogen
complex suppressed the formation of new atherosclerotic lesions in post-
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menopausal women [213, 225].
6. HERBAL TREATMENT OF CEREBROVASCULAR DISORDERS
Cerebrovascular disorders involve different kinds of diseases, such as stroke,
cerebral edema, vascular dementia, and transient ischemic attack, in addition to
age-associated memory impairment which is experienced by elderly people, as
dizziness, depression, and tinnitus [226]. Regrettably, the mortality data conveyed
to the WHO by different countries are inconsistent [227]. However, these
diseases, especially stroke, represent the third leading cause of death in the United
States after heart diseases and cancer [226].
This category of diseases is considered as a type of peripheral vascular diseases.
They occur as a consequence of the brain cells dysfunction, which happens due to
free radicals including superoxide, hydrogen peroxide and hydroxylation radicals
or decreased oxygenation level. This part of the chapter will focus mainly on the
second point; major causes of decreased oxygen level supplied to brain neuronal
cells and its possible herbal treatment.
Cerebral tissues consume approx. 20% of the total body requirement from oxygen
to live and work properly. Deficiency of oxygen supply in cerebral tissues has
many reasons, which could be classified into abnormalities of the vessels
supplying the blood to the brain due to atherosclerosis or arthritis or abnormalities
in the blood flow itself. Diseases in blood vessels provoke secretion of plateletactivating factor (PAF) and thrombus formation. Thrombosis or embolism
reduces the oxygen supply to the cerebral tissues significantly and results in tissue
hypoxia or ischemia affecting the blood flow and tissue oxygenation as well.
Major developments in treating ischemic stroke have been performed over the last
decade. However, stroke is still a serious concern for which effective drug therapy
is not yet available [228]. To date, the FDA only approved Recombinant
plasminogen activator (rt-PA) for the treatment of stroke. However, thrombolysis
lessens stroke morbidity but is only relevant to a small percentage of stroke
patients [229].
6.1. Physiology and Pathophysiology of Blood Coagulation
Physiologically, blood coagulation systems or hemostasis functions through
extrinsic and intrinsic pathways that are promoted differently via tissue injury or
abnormal pathological conditions. However, they joined in a common pathway at
the conversion step of thrombin from prothrombin.
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Coagulation cascades are monitored through a number of clinical laboratory tests,
such as APTT for the intrinsic pathway, PT for extrinsic pathway, and TT for
common pathway. In addition, International Normalized Ratio (INR) or
standardized prothrombin time is sometimes required especially for patients
taking anti-clotting medicines, such as warfarin.
6.2. Natural Treatments of Coagulation Abnormalities
Natural herbal antioxidants are out of scope of this part. Therefore, a number of
herbal treatments that could be used to alleviate symptoms of thrombosis and
resulting cerebrovascular disorders will be covered in the following section.
6.2.1. Ginkolides and Bilobalides
Ginko tree (Ginko biloba L., Ginkoaceae) is always described by the “living
fossil”. Additionally, it has a long history, some 2000 years especially in China, in
treating many diseases. Ginkgo biloba is amongst the best seller medicinal plants
with 4.5 to 5.1 million pounds annual consumption in 2001 of the dried leaves.
Currently there are about 142 G. biloba products on the market worldwide and its
utilization is estimated to grow threefold in the upcoming five years [230].
Standardized leaf extracts of G. biloba (SGB extracts) have neuroprotective
activities. In addition, it may be useful in preventing and treating CVD, mainly
ischemic cardiac syndrome [231, 232].
These bioactivities owe to its mixture contents from flavonol and biflavone
glycosides, such as quercetin and kaempferol, in addition to sesquiterpene and
diterpene lactones, including bilobalide and ginkolides, respectively. Flavonoid
contents enhance the capillary integrity in addition to its function as free-radical
scavengers as well [233]. While terpene lactones work as platelet-activating factor
inhibitors produced by different tissues. This function prevents platelet
aggregation and its subsequent thrombus formation.
6.2.2.. Sulphated Polysaccharides
Marine macroalgae produce sulphated and non-sulphated polysaccharides
possessing a wide-range of interesting medical applications making them
promising pharmaceutical products [234]. Among them are Phaeophytes or brown
algae polysaccharides, e.g., fucoidan, alginate and laminarin. Several reports
investigated the potential anticoagulant activity of the sulphated polysaccharide
fucoidan [235 - 237]. They reported that it acts in a heparin-like manner and
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interfered mainly with the intrinsic pathway of the coagulation system [238, 239].
In addition, the negative charge distribution of its structure together with its long
polysaccharide chain, high molecular weight, and structure comfort ability
contributed to inhibition of thrombin and discontinuation of the fibrinogen
conversion to fibrin [240].
6.2.3. Garlic Thiosulphinates
Chemistry and biology of garlic (Allium sativum L., family Alliaceae) have been
intensively investigated as one of the most investigated medicinal plants. More
than 3000 research articles were published in the last few decades during 1960 to
2007. Most of these studies focused on the possible indication of garlic in
treatment of CVD [241]. Garlic contains over a hundred 100 sulfur-containing
metabolites. Allicin represents 70-80% of the total thiosulphinates. The antiplatelet activity of garlic has been attributed to adenosine, allicin and other
thiosulfinates [242].
6.2.4. Extract of Antrodia camphora
A. camphorate is a fungal parasite that lives and grows on Cinnamomum
kanehirae (Bull camphor tree) Hayata (Lauraceae) [243]. Polysaccharides,
terpenoids, lignans, benzenoids, benzoquinone derivatives have been identified.
Pharmacologically, it is used in Traditional Chinese Medicine (TCM) for the
treatment of viral hepatitis and cancer, yet, it has shown neuroprotective effects in
embolic rats, recently [228]. It is useful in reestablishing blood flow to the
ischemic brain through the reduction of perfusion deficits following ischemia and
without causing any hemorrhagic incidence when used in conjunction with aspirin
therapy [244].
6.2.5.. Alpha-lipois Acid
Alpha-lipoic acid or ALA is found in various foods. It shows a significant part in
metabolic processes. It functions as a cofactor for several key enzymes. It has
been known as the “perfect” antioxidant [245]. It protects against oxidation, thus
prevents Ischemia-reperfusion injury [245]. It attenuates middle cerebral artery
occlusion-induced cerebral ischemia and reperfusion injury. It acts via insulin
receptor-dependent and PI3K/Akt-dependent inhibition of NADPH oxidase.
Moreover, an interesting study established the effects of Tetra Methyl Pyrazine
(TMP) on functional recovery and neuronal dendritic plasticity after experimental
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stroke. In that study, the authors have demonstrated that enhanced dendritic
plasticity contributes to TMP-elicited functional recovery after ischemic stroke
[246].
CONCLUDING REMARKS
The increase in the popularity of the use of natural products has raised the interest
in natural remedies that can be beneficial in the treatment of cardiovascular
diseases. This chapter highlights the cardiovascular effects of natural products and
their metabolites in controlling cardiovascular diseases especially those subjected
to sub-clinical or clinical trials. Although most of the mentioned plants have a
long history in treating heart diseases, recent research strategies show how
efficient they are in the treatment of different cardiovascular diseases including
ischemic heart disease, congestive heart failure, and hypertension by unique
mechanisms. In addition, we also discussed the chemical constituents of these
plant species which provide beneficial effects by various modes of action that can
improve the quality of life in patients with heart disease and potentially save their
lives.
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